Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 1(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01289938Phase 1Terminated

Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

Role: lead

NCT01788254Phase 1Completed

Open Label Study for the Functional Characterization of Drug Metabolism and Transport

Role: lead

NCT00537732Phase 4Terminated

Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

Role: lead

All 3 trials loaded